Siddiqui Bilal A, Zhang Miao, Pisters Louis L, Tu Shi-Ming
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Transl Androl Urol. 2020 Jan;9(Suppl 1):S56-S65. doi: 10.21037/tau.2019.09.11.
Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification of testicular cancers, and reviews the current state of knowledge and standard of care for the systemic treatment of testicular germ cell tumors with chemotherapy, focusing on the relevant clinical data supporting each treatment regimen. This review also briefly highlights current areas of active investigation, notably in the relapsed and refractory setting, including ongoing clinical trials.
睾丸生殖细胞肿瘤是年轻男性中最常见的实体瘤。这些癌症代表了现代医学在治愈年轻患者并给予数十年生命方面的成功案例，其5年生存率约为95%。本综述概述了睾丸癌的分期和风险分类，并回顾了睾丸生殖细胞肿瘤全身化疗的当前知识状况和治疗标准，重点关注支持每种治疗方案的相关临床数据。本综述还简要强调了当前积极研究的领域，特别是在复发和难治性情况下，包括正在进行的临床试验。
